Live Breaking News & Updates on Division Of Urologic Oncology

Stay updated with breaking news from Division of urologic oncology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Limmi adds Oncobiomix as customer of Disease Insights Platform, powering microbiome-based risk prediction for cancer

Limmi adds Oncobiomix as customer of Disease Insights Platform, powering microbiome-based risk prediction for cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United States , Bryan Ivory , Technology Officer , Department Of Urology , Division Of Urologic Oncology , Disease Insights Platform , Michael Liss , Urologic Oncology , Texas Health Science Center San , Limmi President , Chief Technology ,

Dr Singer on the Safety of Perioperative Nivolumab and Cabozantinib in RCC

Eric A. Singer, MD, discusses the safety of perioperative nivolumab and cabozantinib in patients with metastatic clear cell renal cell carcinoma.
....

United States , Division Of Urologic Oncology , American Urological Association Annual Meeting , Ohio State University Comprehensive Cancer Center , Ohio State University Wexner Medical Center , Urologic Oncology , Urological Association Annual Meeting , The Ohio State University Comprehensive Cancer Center James Hospital Amp Solove Research Institute , Usuccc James , Genitourinary Cancers , Onclive Tv ,

Pembrolizumab Could Delay Radical Cystectomy in BCG-unresponsive, High-risk NMIBC

Eric A. Singer, MD, discusses the findings from cohort B of KEYNOTE-057 and explains why systemic therapy with pembrolizumab could be beneficial for patients with Bacillus Calmette-Guérin–unresponsive, high-risk, papillary-only non–muscle invasive bladder cancer who hope to avoid radical cystectomy. ....

United States , Ohio State University , Astellas Medivation , Ohio State University Comprehensive Cancer Center , Ohio State University Wexner Medical Center , American Urological Association , Division Of Urologic Oncology , Bacillus Calmette Gu , Urological Association , Annual Meeting , Urologic Oncology , Merck Sharp , Bacillus Calmette Guerin , Keynote 057 Trial , Bacillus Calmette Guérin , Non Muscle Invasive Bladder Cancer , Erica Singer , American Urological Association Annual Meeting , Aua Annual Meeting ,

Dr Singer on Systemic Pembrolizumab Monotherapy in BCG-unresponsive High-Risk NMIBC

Eric A. Singer, MD, discusses the use of systemic pembrolizumab monotherapy in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle invasive bladder cancer. ....

Ohio State University Comprehensive Cancer Center , Division Of Urologic Oncology , Ohio State University Wexner Medical Center , Urologic Oncology , Bacillus Calmette Gu , Pembrolizumab Monotherapy , Erica Singer , Bacillus Calmette Guérin Bcg Unresponsive , High Risk Non Muscle Invasive Bladder Cancer ,

Pembrolizumab Monotherapy Demonstrates Clinical Efficacy in High-risk NMIBC

Treatment with pembrolizumab monotherapy resulted in stable long-term disease-free survival rates in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer. ....

United States , Ohio State University Comprehensive Cancer Center , American Urological Association Annual Meeting , Ohio State University Wexner Medical Center , Division Of Urologic Oncology , Bacillus Calmette Gu , Urological Association Annual , Urologic Oncology , Ohio State University Comprehensive Cancer , Pembrolizumab Monotherapy , Patients With Bacillus Calmette Guérin Unresponsive , High Risk Non Muscle Invasive Bladder Cancer , Keynote 057 Trial , Erica Singer , The Ohio State University Wexner Medical Center , The Ohio State University Comprehensive Cancer Center ,